PMID- 9402851
OWN - NLM
STAT- MEDLINE
DCOM- 19980105
LR  - 20190921
IS  - 0939-5555 (Print)
IS  - 0939-5555 (Linking)
VI  - 75
IP  - 4
DP  - 1997 Oct
TI  - Subcutaneous low-molecular-weight heparin for treatment of Trousseau's syndrome.
PG  - 165-7
AB  - We report the case of a 76-year-old man with recurrent thromboses despite oral 
      anticoagulation with phenprocoumon and low-grade chronic disseminated 
      intravascular coagulation. Workup revealed a bronchial carcinoma (NSCCL) with 
      hilar and mediastinal lymph node metastases. The clinical condition was 
      consistent with Trousseau's syndrome. Based on reports in the literature, the 
      therapy was changed to intravenous unfractionated heparin (UFH), which was 
      effective in controlling the thrombotic coagulopathy. For practical reasons, 
      despite a lack of evidence of its effectiveness in Trousseau's syndrome, therapy 
      with UFH was changed to subcutaneous low-molecular-weight heparin (LMWH, 
      nadroparine) in therapeutic doses of 100 IU/ kg body wt. 12 hourly. On an 
      outpatient basis, five chemotherapy cycles were administered, and after 
      metastases of the brain had been detected radiotherapy was initiated. Following 
      7.5 months of progressive neoplastic disease the patient died. He had remained 
      free of thromboembolic complications under continued LMWH therapy during the last 
      6.5 months of his life. LMWH might be a convenient alternative to the established 
      therapy with UFH in Trousseau's syndrome.
FAU - Zuger, M
AU  - Zuger M
AD  - Central Hematology Laboratory, Inselspital, University Hospital of Bern, 
      Switzerland.
FAU - Demarmels Biasiutti, F
AU  - Demarmels Biasiutti F
FAU - Wuillemin, W A
AU  - Wuillemin WA
FAU - Furlan, M
AU  - Furlan M
FAU - Lammle, B
AU  - Lammle B
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
RN  - 0 (Anticoagulants)
RN  - 0 (Nadroparin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Carcinoma, Bronchogenic/complications
MH  - Carcinoma, Non-Small-Cell Lung/complications
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Lung Neoplasms/complications
MH  - Male
MH  - Nadroparin/administration & dosage/*therapeutic use
MH  - Paraneoplastic Syndromes/complications/*drug therapy
MH  - Thrombophlebitis/complications/*drug therapy
EDAT- 1997/12/24 00:00
MHDA- 1997/12/24 00:01
CRDT- 1997/12/24 00:00
PHST- 1997/12/24 00:00 [pubmed]
PHST- 1997/12/24 00:01 [medline]
PHST- 1997/12/24 00:00 [entrez]
AID - 10.1007/s002770050336 [doi]
PST - ppublish
SO  - Ann Hematol. 1997 Oct;75(4):165-7. doi: 10.1007/s002770050336.